Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc has a strong liquidity position, with cash and equivalents amounting to $86.0 million, which is significantly higher than its total liabilities of $46.0 million, resulting in a current ratio of 8.95. The company's price-to-book ratio of 0.92 suggests that the market value is slightly below the book value, indicating potential undervaluation or investor skepticism about future earnings. The company is currently unprofitable, with a net loss of $11.4 million and an operating loss of $12.4 million in the latest reporting period. Its return on equity (ROE) is -25.9%, and return on assets (ROA) is -12.6%, both significantly below the industry norms for biotechnology firms, which typically require high R&D investment and long development cycles before achieving profitability. Actinium Pharmaceuticals Inc operates as a single business segment, with no disclosed geographic diversification in its revenue streams. The company's operations are entirely focused on the development of Iomab-B, a targeted alpha therapy for hematologic malignancies, with no other products currently generating revenue. The company is in a development phase, with no revenue reported in the latest financial snapshot. Analysts have assigned a mean price target of $5.00, suggesting a potential upside of 290% from the current market price of $1.28. However, the company's operating cash flow of -$15.3 million and free cash flow of -$11.2 million indicate ongoing cash burn, which will need to be managed as it progresses through clinical trials and regulatory approvals. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low debt-to-equity ratio of 0.0, as it has no long-term debt, and its equity base of $43.8 million is supported by a strong cash position. However, the company's reliance on equity financing for future operations could introduce dilution risk if it needs to raise additional capital to fund its development pipeline. Recent events include the continued development of Iomab-B, with the company preparing for potential regulatory submissions. No recent filings or transcripts indicate significant changes in strategy or operations, and the company remains focused on its core therapeutic area.